Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Stephens Fall Investment Conference 2015
19 slides from Staar Surgical's conference presentation, Nov 10, 2015
Slide 1: Stephens Fall Investment Conference
Stephens Fall Investment Conference November 10, 2015 NASDAQ: STAA 1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about any of the following: any projections of earnings, revenue, sales, profit margins, cash, effective tax rate or any other financial item
Slide 3: STAAR Surgical Is… Premium Implantable Lenses for Refractive Vision Correction
STAAR® SURGICAL IS… … a Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses for Refractive Vision Correction • Implantable Collamer® Lens or “ICL”™ - A Premium Refractive Procedure and an Alternative to LASIK - >550,000 Visian® ICLs Implanted 70% YTD 2015 Lenses 3
Slide 4: STAAR Surgical Is… Premium Implantable Lenses for Cataract Lens Replacement
STAAR SURGICAL IS… … a Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses for Cataract Lens Replacement • Intraocular Lens (IOL) - Used to Replace the Natural Lens after Cataract Surgery 30% YTD 2015 Lenses 4
Slide 5: Refractive Market 2017
REFRACTIVE MARKET 2017 WW Refractive Market by Region 2014-2017 Growth Rate Total Procedures 3.3 Million Total Procedures 3.9 Million % by Region 3-year CAGR = 5.6% Year 2014 Source: Market Scope
Slide 6: Top Countries – Refractive Procedures
TOP 10 COUNTRIES – REFRACTIVE PROCEDURES - China 875,000 - USA 602,000 - India 156,430 - South Korea 139,280 - Germany 135,000 - Japan 125,000 - Italy 105,240 - Spain 105,000 - Brazil 102,580 - UK 97,540 Source: Market Scope
Slide 7: STAAR Approach to the Market
STAAR APPROACH TO THE MARKET 2014 Now • Focused on Lenses Inserted into the Eye and Delivery • Focused on Lenses Inserted into the Eye with Companion Systems Therefor Delivery Systems Delighting Surgeons and Their Patients • Two Large Market Opportunities • Three Large Vision Enhancement Opportuniti
Slide 8: Our Focus 2015 - 2017 for Consistent Growth
OUR FOCUS 2015 - 2017 BUILDING A FOUNDATION FOR CONSISTENT GROWTH • Engender Culture of Quality - FDA Remediation and Systemic Change • Build R & D Continuum: CentraFLOW®/ Presbyopia/ Cataract Care • Invest in Proprietary Technology and Process Improvements • Develop Global Clinical Validation and C
Slide 9: Our Focus 2015 - 2017: Culture of Quality and FDA Remediation
OUR FOCUS 2015 - 2017 BUILDING A FOUNDATION FOR CONSISTENT GROWTH • Culture of Quality - FDA Remediation and Systemic Change & Upgrade - Diligently Focus on Meeting or Exceeding Remediation Requirements: Meeting Internal Metrics - Hire Top Talent to Manage and Direct Systemic Correction and Upgrade:
Slide 10: Our Focus 2015 - 2017: Build R&D Continuum
OUR FOCUS 2015 - 2017 BUILDING A FOUNDATION FOR CONSISTENT GROWTH • Build R & D Continuum: CentraFLOW®/ Presbyopia/ Cataract Care Dr. Jose F. Alfonso MD, PhD and colleagues published a paper on ICL results in the April 2015 issue of the Journal of Cataract and Refractive Surgery. In a study of 3430
Slide 11: Our Focus 2015 - 2017: R&D Continuum, New VP R&D
OUR FOCUS 2015 - 2017 BUILDING A FOUNDATION FOR CONSISTENT GROWTH • Build R & D Continuum: CentraFLOW®/ Presbyopia/ Cataract Care Hired Dr. Keith Holliday VP R&D - Supporting Remediation - Presbyopic ICL Development - Materials and Engineering Projects - New Categories of Lens Development - New Deli
Slide 12: Our Focus 2015 - 2017: Proprietary Technology and Process Improvements
OUR FOCUS 2015 - 2017 BUILDING A FOUNDATION FOR CONSISTENT GROWTH • Invest in Proprietary Technology and Process Improvements - Building Research Lab for Materials Science with Emphasis on Next Generation Collamer® Versions 2016/17 - Assessing Opportunities to Expand Patent Estate (Patents and Trade
Slide 13: Our Focus 2015 - 2017: Global Clinical Validation
OUR FOCUS 2015 - 2017 BUILDING A FOUNDATION FOR CONSISTENT GROWTH • Enhance Global Clinical Validation and Clinical Utility Competency - Recruited Clinically Lauded Ophthalmic Surgeons for Working Groups in Presbyopia and Sizing • We have created a Clinical Affairs Department led by industry recogni
Slide 14: Our Focus 2015 - 2017: Surgeon and Patient Experience
OUR FOCUS 2015 - 2017 BUILDING A FOUNDATION FOR CONSISTENT GROWTH • Create an Extraordinary Surgeon and Patient Experience: - Prof. Kimiya Shimizu – authored a paper with other leading doctors from Japan, published in December of 2014 in the Journal of Cataract and Refractive Surgery. It provided th
Slide 15: Our Focus 2015 - 2017 for Consistent Growth
OUR FOCUS 2015 - 2017 BUILDING A FOUNDATION FOR CONSISTENT GROWTH • Engender Culture of Quality - FDA Remediation and Systemic Change • Build R & D Continuum: CentraFLOW®/ Presbyopia/ Cataract Care • Invest in Proprietary Technology and Process Improvements • Develop Global Clinical Validation and C
Slide 16: Recent Financial Results: Q3 2015 GAAP
RECENT FINANCIAL RESULTS Q3 2015 GAAP ($ millions, except per share) Income Statement Q3 2015 Q3 2014 Revenue $ 18.8 $ 18.2 Gross Profit $ 12.8 $ 11.9 Gross Profit Margin 68.3% 65.3% Operating Expenses $ 14.8 $ 13.4 Other Income (Loss) $ 0.3 $ (0.6) Income (Loss) Before Taxes $ (1.8) $ (2.2) Net Inc
Slide 17: Recent Financial Results: Q3 2015 Non-GAAP
RECENT FINANCIAL RESULTS Q3 2015 Non-GAAP ($ millions, except per share) Adjusted Net Income Q3 2015 Q3 2014 Net Income (Loss) $ (1.8) $ (2.7) Foreign Currency Impact - $ 0.6 Stock-Based Compensation Expense $ 0.9 $ 1.6 FDA Panel / Remediation Expense $ 0.8 $ 0.6 Adjusted Net Income (Loss) - $ 0.1 A
Slide 18: Q3 Financial Highlights
Q3 FINANCIAL HIGHLIGHTS • Sales of $18.8M: +3% from Prior Year and +7% in Constant Currency - ICL units increased 21% WW: +37% in EMEA; +13% in APAC; +10% in NA • Gross Margin Improved 300 bps: 68.3% Compared to Prior Year of 65.3% - Favorable product mix, lower unit costs, and higher avg. selling p
Slide 19: Stephens Fall Investment Conference
Stephens Fall Investment Conference November 10, 2015 NASDAQ: STAA 19
STAAR Surgical Company — Stephens Fall Investment Conference 2015 on 6ix